B-cell adult acute lymphoblastic leukemia
Information
- Disease name
- B-cell adult acute lymphoblastic leukemia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01925131 | Completed | Phase 1 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | June 13, 2014 | January 1, 2023 |
| NCT00052520 | Completed | Phase 1/Phase 2 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | September 2002 | June 2013 |
| NCT00061945 | Completed | Phase 1/Phase 2 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | June 2003 | October 2012 |
| NCT00867529 | Completed | Phase 2 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | February 2009 | March 26, 2015 |
| NCT00873093 | Completed | Phase 2 | Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | March 2009 | September 2014 |
| NCT00918333 | Completed | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | June 2009 | July 16, 2019 |
| NCT01029366 | Completed | Phase 1 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | March 17, 2010 | May 2016 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01258998 | Completed | Phase 2 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | December 2010 | August 2015 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT00010192 | Completed | Phase 1 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | December 2000 | |
| NCT03097770 | Completed | Phase 1/Phase 2 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | April 1, 2017 | January 31, 2020 |
| NCT02228772 | Completed | Phase 1 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | December 2014 | November 2019 |
| NCT04044560 | Terminated | Phase 2 | Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant | September 8, 2020 | February 2, 2022 |
| NCT02168907 | Terminated | Phase 1 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | December 2014 | February 2015 |
| NCT01735604 | Unknown status | Phase 1/Phase 2 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | January 2013 | October 2018 |
| NCT03110640 | Unknown status | Phase 1 | Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | October 1, 2016 | September 2021 |
| NCT03185494 | Unknown status | Phase 1/Phase 2 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | August 1, 2017 | August 1, 2020 |
| NCT02685670 | Unknown status | Phase 1/Phase 2 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma | February 2016 | December 2019 |
| NCT01864889 | Unknown status | N/A | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | April 2013 | April 2017 |
| NCT02281279 | Withdrawn | Phase 1/Phase 2 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | October 2016 | |
| NCT01670084 | Withdrawn | Phase 2 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia | December 2012 | September 2017 |